[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-cell-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-cell-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100638863","phase-3-evaluate-bl-m14d1-plus-atezolizumab-vs-standard-of-care-in-first-line-extensive-stage-small-cell-lung-cancer-100638863",false,"NCT07625644","Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer","A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed first-line (1L), extensive-stage (ES) small cell lung cancer (SCLC)\n* Must be eligible to receive a platinum-based chemotherapy regimen in combination with an anti-PD-L1 inhibitor.\n* At least one measurable lesion based on RECIST v1.1 per investigator assessment.\n* An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Received any kind of platinum or etoposide treatment for limited stage (LS) SCLC within 6 months prior to enrollment.\n* Participants who have received prior topoisomerase inhibitor-based ADC therapy.\n* Participants with history of severe heart disease\n* Participants with active autoimmune diseases and inflammatory diseases,\n* Participants with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and\u002For carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.","ALL","18 Years",{"count":19,"type":20},550,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).",[26,27,28,29,30,31,32,33],"Small Cell Lung Cancer Extensive Stage","Small-cell Lung Cancer","Small Cell Carcinoma","Sclc","SCLC,Extensive Stage","Lung Cancer","Lung Cancer Metastatic","Lung Cancer Stage IV",[35,36],"DLL3","First Line","NOT_YET_RECRUITING","2026-05-28",{"date":40,"type":41},"2026-06-04","ACTUAL",{"date":43,"type":20},"2026-06",{"date":45,"type":20},"2031-06",{"name":47,"class":48},"SystImmune Inc.","INDUSTRY",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100608823","phase-1-penfluridol-for-relapsedrefractory-small-cell-cancers-100608823","NCT07206563","Penfluridol for Relapsed\u002FRefractory Small Cell Cancers","Penfluridol for Relapsed\u002FRefractory Small Cell Lung Carcinoma and Small Cell Cervical Cancer: An Open-Label, Multicenter, Single-Arm Ib\u002FII Trial","Inclusion Criteria:\n\n1. Patients aged 18 to 75 years, inclusive, regardless of gender.\n2. Histologically or cytologically confirmed small-cell carcinoma of the lung or cervix that is not curable by surgery or radiochemotherapy.\n3. Have received at least two prior systemic treatment regimens, including etoposide and platinum-based chemotherapy, and have experienced disease progression.\n4. No receipt of investigational or approved cytotoxic chemotherapy within 28 days before enrollment; no receipt of alkylating agents within 42 days before enrollment; no receipt of investigational or approved targeted therapy within 28 days or 5 half-lives before enrollment (whichever is shorter, but not less than 14 days); no radiotherapy within 14 days before enrollment.\n5. Presence of measurable disease according to RECIST 1.1 criteria; measurable lesions are defined as lesions that can be accurately measured in at least one dimension (longest diameter ≥10 mm on CT or MRI scans, and lymph nodes with short-axis diameter ≥15 mm).\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Expected survival of ≥12 weeks.\n8. Recovery of prior anticancer treatment toxicities to ≤Grade 1 (except for alopecia, pigmentation, or other toxicities deemed non-safety risks by the investigator); for irreversible toxicities that are not expected to worsen with study drug administration (e.g., hearing loss), inclusion may be considered after consultation with the medical monitor. Recovery of peripheral neuropathy to ≤Grade 2 after prior use of cisplatin or etoposide may be considered for inclusion after consultation with the medical monitor. For late toxicities caused by radiotherapy that cannot be recovered, inclusion may be considered after consultation with the medical monitor.\n9. Laboratory tests: Absolute neutrophil count ≥1.5×10⁹\u002FL; platelets ≥75×10⁹\u002FL; hemoglobin ≥90 g\u002FL; serum creatinine ≤1.5 times the upper limit of normal (ULN); urine protein \\\u003C2+ or 24-hour urine protein \\\u003C1.0 g; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times ULN (or ≤5 times ULN in the presence of liver metastasis); total bilirubin ≤1.5 times ULN; albumin ≥28 g\u002FL; coagulation function: prothrombin time (PT) and international normalized ratio (INR) ≤1.5×ULN.\n10. Female subjects with negative urine or blood HCG (except for menopausal and hysterectomy cases); sexually active female subjects and their partners must agree to use effective contraception (e.g., combined hormonal contraception, intrauterine device, bilateral tubal ligation, vasectomy, abstinence) during the study and for 6 months after the last dose.\n11. Availability of tumor specimens (paraffin-embedded blocks or frozen tissue) from prior resection or biopsy sufficient for pharmacodynamic assays (≥3 slides for immunohistochemistry IHC) (mandatory for dose-expansion cohort patients only).\n12. Ability to understand the study and voluntary consent to participate in the trial by the patient or their legal representative, with signed informed consent.\n\nExclusion Criteria:\n\n1. Histological diagnosis of squamous cell carcinoma, adenocarcinoma, or other non-small-cell types of lung or cervical cancer.\n2. Concurrent enrollment in another clinical trial, unless it is an observational, non-interventional study or the follow-up period of an interventional study.\n3. Known hypersensitivity to any component of penfluridol or similar compounds with comparable chemical or biological properties.\n4. Prior exposure to penfluridol.\n5. Known presence of leptomeningeal metastasis, spinal cord compression, leptomeningeal disease, or active brain metastases. However, patients with asymptomatic brain metastases (no neurological deficits, seizures, or other typical symptoms and signs of central nervous system metastasis; no requirement for corticosteroids) or those who have been treated and are stable on imaging for at least 4 weeks before study treatment (with no new or enlarged brain metastases) and have discontinued systemic corticosteroids and anticonvulsant medications for at least 2 weeks may be included.\n6. Uncontrolled comorbid conditions, including but not limited to persistent or active infections or psychiatric\u002Fsocial conditions that would limit compliance with study requirements.\n7. Positive for human immunodeficiency virus (HIV) on combination antiretroviral therapy.\n8. Cardiovascular history or comorbidities: Known history of arrhythmias (including atrial fibrillation, tachycardia, or bradycardia), except for benign ventricular premature beats; history of CHF, MI, or stroke within the past 3 months.\n9. History of seizure within the past 3 months.\n10. Gastrointestinal dysfunction or disease that may significantly alter the absorption of penfluridol (e.g., uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).\n11. Known history of allogeneic organ transplant or allogeneic hematopoietic stem cell transplant.\n12. Uncontrolled severe medical conditions that, in the opinion of the investigator, would affect the patient's ability to receive the study treatment, such as severe internal medicine conditions, including hepatic or renal insufficiency, severe cardiovascular disease, cerebrovascular disease, uncontrolled diabetes, or uncontrolled infections.\n13. Pregnant or breastfeeding women; sexually active female subjects unwilling to use contraception.\n14. Presence of symptomatic or unstable pleural effusion, ascites, or pericardial effusion requiring repeated drainage.\n15. Patients deemed unsuitable for the study by the investigator.","75 Years",{"count":58,"type":20},33,[60,61],"PHASE1","PHASE2","Penfluridol for Relapsed\u002FRefractory Small-Cell Carcinoma of the Lung or Cervix: A Multicenter, Open-Label, Single-Arm Phase Ib\u002FII Trial This study evaluates the safety and anti-tumor activity of oral penfluridol, a first-generation antipsychotic that pre-clinically inhibits small-cell carcinoma (SCC) growth via DRD2 blockade, metabolic reprogramming and apoptosis induction. After ≥2 prior systemic regimens, 33 adult patients (18-75 y) with measurable, metastatic or recurrent lung or cervical SCC will be enrolled across five Chinese centers. A 3+3 dose-escalation (Ib) will establish the recommended Phase II dose (RP2D); an expansion cohort (II) will examine objective response rate (ORR, RECIST 1.1). Secondary end-points include duration of response, progression-free survival, overall survival, safety and exploratory biomarkers. Key inclusion: ECOG 0-1, adequate organ function, no active brain metastases. Penfluridol is administered once weekly, dose-escalated from 20 mg to RP2D, continued until progression or intolerance. Patients receive free study drug, PET imaging and laboratory monitoring.",[28,64,65,66],"Small Cell Carcinoma of Lung","Small Cell Lung Cancer ( SCLC )","Small Cell Cervical Carcinoma",[68,69,70,71,72],"Small cell cervical carcinoma","small cell lung carcinoma","Relapsed\u002Frefractory","Phase Ib\u002FII","DRD2 targeting","2025-09-25",{"date":75,"type":41},"2025-10-03",{"date":77,"type":20},"2025-10-01",{"date":79,"type":20},"2028-10-01",{"name":81,"class":82},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":83},"100487035","quantifying-systemic-immunosuppression-to-personalize-cancer-therapy-100487035","NCT05621837","Quantifying Systemic Immunosuppression to Personalize Cancer Therapy","Serpentine","Inclusion Criteria\n\n* Histologically documented diagnosis of metastatic\u002Flocally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included\n* Will and ability to comply with the protocol\n* Willingness and ability to provide an adequate archival Formalin-Fixed Paraffin-Embedded (FFPE) tumor sample available for exploratory biomarker analysis\n* Age from 18 to 90 years at the time of recruitment\n* ECOG Performance Status \\\u003C= 2\n* Understanding and signature of the informed consent\n* Consenting to participate to the socio-economical-psychological survey\n\nExclusion Criteria\n\n* Known history of HIV infection\n* Serious neurological or psychiatric disorders\n* Pregnancy or lactation\n* Inability or unwillingness of participant to give written informed consent\n* Inability or unwillingness to be regularly followed up at the same center",true,"90 Years",{"count":94,"type":20},1000,"OBSERVATIONAL","The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood.",[98,99,100,101,102,28,103],"Melanoma","Breast Cancer","Renal Cell Carcinoma","Urinary Bladder Cancer","Squamous Cell Carcinoma of Head and Neck","NSCLC","RECRUITING","2025-04-29",{"date":107,"type":41},"2025-05-02",{"date":109,"type":41},"2022-03-10",{"date":111,"type":20},"2026-12-31",{"name":113,"class":82},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"]